Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology.
Ben Toumia I, Bachetti T, Chekir-Ghedira L, Profumo A, Ponassi M, Di Domizio A, Izzotti A, Sciacca S, Puglisi C, Forte S, Giuffrida R, Colarossi C, Milardi D, Grasso G, Lanza V, Fiordoro S, Drago G, Tkachenko K, Cardinali B, Romano P, Iervasi E, Vargas GC, Barboro P, Kohnke FH, Rosano C.
Ben Toumia I, et al. Among authors: tkachenko k.
Front Pharmacol. 2024 Jan 3;14:1258108. doi: 10.3389/fphar.2023.1258108. eCollection 2023.
Front Pharmacol. 2024.
PMID: 38235113
Free PMC article.